Medication-Assisted Treatment: What It Is, What It Shows On Tests, How Long It Lasts

Medication-assisted treatment is the use of an approved medication to treat a substance use disorder, delivered alongside counselling and psychosocial support rather than in place of it.

Six medications are approved in the United States, and they split cleanly by substance. For alcohol use disorder: naltrexone, acamprosate and disulfiram. For opioid use disorder: methadone, buprenorphine and naltrexone. Naltrexone appears on both lists because it works on the same receptor system in both conditions.

Two things are worth establishing at the outset, because most of the confusion in this area comes from getting them backwards. The medication is not a support for the treatment — it is the treatment, with therapy built around it. And it is not a short bridge to an unmedicated state. Duration is decided by benefit, not by a schedule.

There is no approved medication for stimulant use disorder — cocaine or methamphetamine. That gap is real, it is not a failure of any particular programme, and where a stimulant is the primary substance the evidence points to behavioural approaches such as contingency management instead.

If you have noticed clinicians saying "MOUD" where they used to say "MAT", this is why — and it is more than a preference about words.

Federal agencies now favour "medications for opioid use disorder" (MOUD). The reasoning is stated plainly in the guidance: the term "medication-assisted treatment" implies that the medication has a supplemental or temporary role. Using MOUD instead aligns these medications with how other psychiatric medications are understood — antidepressants, antipsychotics — as central tools in the treatment plan rather than accessories to it.

SAMHSA has been formalising the change, including in the terms and conditions attached to grant funding from the 2026 fiscal year onward. In practice you will encounter both terms for years yet: "MAT" is embedded in insurance policies, state regulations, programme names and search habits.

Why it matters practically rather than politically: the old word shaped expectations that harmed people. If medication is "assisted" treatment, then stopping it looks like graduation and staying on it looks like incomplete recovery. Both readings are wrong, and both have led people to discontinue a medication that was keeping them alive.

Alcohol medications are dramatically under-prescribed relative to the size of the problem — and unlike the opioid medications, none of them require a specialised programme to obtain.

Here the evidence is unusually strong and unusually specific: federal research associates methadone with 58% lower odds of dying from overdose and buprenorphine with 52%.

Methadone is a full agonist taken as a daily dose that prevents withdrawal and reduces craving. It carries the strongest association with reduced mortality of the three, and in the US it is dispensed through licensed programmes — usually daily attendance at first, which is the main practical constraint.

Buprenorphine is a partial agonist that can be prescribed in an ordinary office and taken at home, which makes it the option that fits around employment. Timing at the start matters: taken too soon after the last opioid dose it can precipitate withdrawal, so induction is planned rather than improvised.

Naltrexone blocks opioid effects entirely and is available as a monthly injection. It is not a withdrawal treatment — full withdrawal must come first, which is the practical hurdle that limits its use.

Our page on opioid use disorder goes into why detox without one of these medications raises rather than lowers overdose risk. That single fact is the most important thing on this site for anyone facing this decision.

This is one of the most-asked questions about these medications and one of the worst-served by the pages that answer it, so here is the accurate version — along with the reason the question is slightly the wrong one.

A standard opioid panel does not flag buprenorphine. Detecting it requires a specific buprenorphine assay, which standard panels do not include by default. For context, the federal DOT panel renamed its "Opiates" category to "Opioids" on 1 January 2018 and covers the common prescription and illicit opioids — buprenorphine is not among them.

Methadone likewise requires its own assay rather than appearing on a general opioid screen. Naltrexone is not an opioid at all, and there is no reason for it to register on an opioid panel.

Now the part that matters more than any of the above. In regulated testing the process protects you, and concealment is what breaks it. A confirmed positive goes to a medical review officer — a physician who contacts the donor privately. A valid prescription disclosed to the MRO is a legitimate medical explanation, and the MRO reports a verified result to the employer without disclosing the underlying medication. The failure mode is not the assay; it is someone hiding a prescription and then having no explanation available when asked.

What we are not going to state as fact: whether a specific medication is compatible with a specific safety-sensitive role — commercial driving, aviation, firearms-carrying positions, certain clinical licences. Those determinations are made by the relevant medical examiner or licensing body under rules that change, and a website that gives you a confident answer is guessing with your career. Ask your prescriber to speak to the examiner directly.

For anyone with a professional licence or a senior role, this is usually the real question underneath the medical one.

Start from the smallest possible disclosure. In most situations that is one person — a medical review officer in the case of testing, or one contact in HR for a leave arrangement — and it can frequently be limited to dates and availability without naming a diagnosis or a medication.

Federal confidentiality rules for substance use treatment records are stricter than for ordinary medical records, which is a genuine protection and one most people do not know they have.

Employment protections exist and are worth knowing before a conversation, not after. Leave for treatment and protections for people in recovery are governed by federal employment and disability law, and executive contracts frequently contain their own provisions that deserve a lawyer's eye before anything is disclosed. Our article on treatment without stepping away from a senior role covers how that is usually structured.

Where a licensing body is involved — medicine, law, aviation, commercial transport — there is often a formal monitoring pathway that is designed to keep people working while treated. These programmes generally respond far better to voluntary disclosure than to discovery, and that difference is worth taking advice on early.

Each medication has a different starting condition, and getting the timing wrong is the most common avoidable problem in this area.

The honest answer disappoints people, and stating it early prevents a worse disappointment later.

There is no fixed course. Medication continues for as long as it provides benefit, which for opioid use disorder in particular is frequently measured in years. A programme presenting a fixed short course, or framing the medication as something to be got off as quickly as possible, is not describing current standard practice.

The comparison that helps is with any other long-term condition. Nobody asks a person on antihypertensives when they will be finished. These disorders involve lasting changes to the systems governing reward, stress and craving, and a medication that stabilises them is not delaying recovery — it is the mechanism of it.

What does change over time is everything around the medication. Therapy intensity tapers, appointments space out, take-home arrangements loosen with stability. The dose is often the last thing to change, and frequently it does not change at all.

One question worth asking at the very first appointment, because it determines whether continuity survives ordinary life events: what happens to my prescription if I move, change insurer, lose coverage or this programme closes? An interruption in medication is not an administrative inconvenience — for opioid use disorder it is a return to the highest-risk state.

Every one of these medications has side effects, and pages that skate over them do people a disservice — because the person who was not warned is the person who stops without telling anyone.

Common and usually manageable: constipation with the opioid agonists, nausea in the early weeks with several of them, sleep disturbance, sweating, headache, and fatigue that generally settles. Acamprosate's most common complaint is diarrhoea. Injectable naltrexone can cause soreness at the injection site.

Worth raising promptly rather than tolerating: persistent nausea or vomiting, marked mood change or new low mood, any yellowing of skin or eyes, unusual tiredness with abdominal pain, or a reaction at an injection site that worsens rather than settles.

The interaction that matters most is with other sedatives. Combining opioid agonists with benzodiazepines or alcohol increases the risk of dangerously slowed breathing. That does not make the combination automatically forbidden — some people are prescribed both for good reasons — but it does mean the prescriber has to know about everything, including what was not prescribed.

And a practical note that prevents a specific emergency: if you take naltrexone, opioid painkillers will not work normally. Carry that information for surgery, dental work or an accident, and tell any treating clinician. Attempting to override the block with higher doses is dangerous.

Coming off is a legitimate goal and a clinical decision, not a test of character.

It is done as a planned taper, gradually, with support in place and with the explicit understanding that tolerance falls as the dose does. For opioid medications that is the whole safety issue: someone who stops and later returns to use faces the same lost-tolerance hazard that makes unsupported detox so dangerous.

The dangerous version of stopping is the unplanned one — a lapse in prescribing, a move, a job change, a programme closing, an insurer refusing a refill. These are the interruptions that account for a substantial share of returns to use, and they are administrative rather than clinical in origin.

Restarting is not a failure. If a taper does not hold, resuming the medication is the correct clinical response and should be available quickly. A programme that treats a return to medication as a relapse to be punished has the logic backwards.

Medication is the least expensive component of effective treatment and the one with the strongest evidence behind it, which makes it a poor place to economise.

Coverage exists but arrives through a different door. Medication is generally billed as a pharmacy benefit rather than inside a programme fee, so what governs your cost is the formulary tier, whether prior authorisation is required, and whether step therapy applies — not the treatment programme's rate.

Three questions settle most of it. Is this medication on my plan's formulary, and at what tier? Does it need prior authorisation, and who submits it? Is the prescriber visit billed separately from the medication?

Generic versions of several of these medications are inexpensive, and long-acting injectable formulations are considerably more costly than daily oral ones — a difference worth discussing openly rather than discovering at the pharmacy. Our guide to insurance coverage covers how to verify a plan before starting.

The phrase "alongside counselling" appears in every official description of this treatment, and it is worth saying what it actually buys.

The medication changes the physiology. It reduces craving, prevents withdrawal, blunts reward. What it does not do is change the circumstances that produced the use, the habits built around it, or the relationships that were damaged by it.

The therapy changes those. Structured approaches — cognitive behavioural therapy, motivational enhancement, contingency management, family work — do the part the medication cannot.

One caveat matters clinically. A requirement to attend counselling should not be a condition of receiving the medication where that requirement becomes a barrier to access. For opioid use disorder, medication alone is far better than nothing, and a programme that withholds a prescription because someone missed groups has inverted the risk. The right structure offers both and does not hold the more effective one hostage to the other.

Which level of therapy fits depends on the picture: outpatient care for most long-term medication management, stepping up to intensive outpatient or day treatment where more structure is needed.

Six questions that establish whether you are being offered current practice.

Everything above describes these medications in general terms. It is not advice about your situation and cannot replace an assessment. Which medication is appropriate, at what dose, and how to start it safely are decisions for a clinician who has taken a full history — including everything else you take, prescribed or not.

If withdrawal from alcohol or benzodiazepines is possible, speak to a clinician before stopping. Withdrawal from either can cause seizures and is a medical emergency.

If you are in immediate danger, call 911. For a suicidal or mental health crisis in the US, call or text 988. For free, confidential treatment referral around the clock, the SAMHSA National Helpline is 1-800-662-HELP (4357).